A novel approach of using Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors to lower uric acid was suggested, and this effect was proposed as one of the possible components of SGLT-2 inhibitors’ pleiotropic effects on cardiovascular diseases by anti-inflammatory actions [41]. Here, SLC5A2 is linked to cardiovascular disorder.